Anticoagulation Therapy

Ozcan Basaran

ISBN 10: 9535126660 / ISBN 13: 9789535126669

Published by Intechopen, 2016

About this Item

nach der Bestellung gedruckt Neuware - Printed after ordering - The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.

Seller Inventory # 9789535126669

Bibliographic Details

• Title: Anticoagulation Therapy
• Publisher: Intechopen
• Publication Date: 2016
• Language: English
• ISBN 10: 9535126660
• ISBN 13: 9789535126669
• Binding: Buch
• Condition: Neu
• Dimensions: 266W x 185H x 15D millimeters 266 millimeters width by 185 millimeters height by 15 millimeters depth
• Weight: 545 grams

About this title

Synopsis

The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase Iii trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.